Cochlear Dysfunction Is a Frequent Feature of Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1).
Journal
Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
ISSN: 1537-4505
Titre abrégé: Otol Neurotol
Pays: United States
ID NLM: 100961504
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
pubmed:
26
9
2020
medline:
22
4
2021
entrez:
25
9
2020
Statut:
ppublish
Résumé
Facioscapulohumeral muscular dystrophy type 1 (FSHD) represents one of the most common forms of muscular hereditary diseases and it is characterized by a great clinical variability with the typical muscular symptoms and other clinical features, including hearing impairment. However, etiopathogenetic mechanisms of auditory dysfunction are still not completely understood and it has been suggested that it could be assigned to a cochlear alteration that is present even in those subjects with a normal pure tonal audiometry (PTA) examination. We found out the cochlear function in 26 patients with molecular diagnosis of FSHD1 and in healthy controls. All patients underwent complete neurological and audiological examinations, including FSHD clinical score, pure-tone audiometry (PTA), and otoacoustic emissions (OAEs), in particular transient evoked otoacoustic emissions (TEOAEs) and distortion product evoked otoacoustic emissions (DPOAEs). All FSHD1 patients showed significantly reduced DPOAEs and TEOAEs, bilaterally and at all frequencies, even when considering only subjects with a normal PTA or a mild muscular involvement (FSHD score ≤ 2). No correlation between OAEs and FSHD clinical score was found. Cochlear echoes represent a sensitive tool in detecting subclinical cochlear dysfunction in FSHD1 even in subjects with normal hearing and/or subtle muscle involvement. Our study is focused on the importance of evaluating the cochlear alteration through OAEs and, in particular, by performing TEOAEs and DPOAEs sequentially, to evaluate more frequent specificities of cochlear dysfunction with a wider spectrum of analysis.
Identifiants
pubmed: 32976345
doi: 10.1097/MAO.0000000000002877
pii: 00129492-202101000-00005
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
18-23Commentaires et corrections
Type : CommentIn
Type : CommentIn
Références
Statland JM, Tawil R. Facioscapulohumeral muscular dystrophy. Continuum (Minneap Minn) 2016; 22:1916–1931.
Tawil R. Facioscapulohumeral Muscular Dystrophy. Vol 148. 1st ed.2018; Amsterdam, Netherlands:Elsevier BV, http://dx.doi.org/10.1016/B978-0-444-64076-5.00035-1
Daxinger L, Tapscott SJ, Van der Maarel SM. Genetic and epigenetic contributors to FSHD. Curr Opin Genet Dev 2015; 33:56–61.
Lemmers RJLF, Tawil R, Petek LM, et al. Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. Nat Genet 2012; 44:1370–1374.
De Greef JC, Lemmers RJLF, Camaño P, et al. Clinical features of facioscapulohumeral muscular dystrophy 2. Neurology 2010; 75:1548–1554.
Tawil R, Kissel JT, Heatwole C, et al. Evidence-based guideline summary: Evaluation, diagnosis, and management of facioscapulohumeral muscular dystrophy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine. Neurology 2015; 85:357–364.
Nikolic A, Ricci G, Sera F, et al. Clinical expression of facioscapulohumeral muscular dystrophy in carriers of 1-3 D4Z4 reduced alleles: Experience of the FSHD Italian National Registry. BMJ Open 2016; 6:e007798.
Lutz KL, Holte L, Kliethermes SA, et al. Clinical and genetic features of hearing loss in facioscapulohumeral muscular dystrophy. Neurology 2013; 81:1374–1377.
Trevisan CP, Pastorello E, Tomelleri G, et al. Facioscapulohumeral muscular dystrophy: Hearing loss and other atypical features of patients with large 4q35 deletions. Eur J Neurol 2008; 15:1353–1358.
Gieron MA, Korthals JK, Kousseff BG, et al. Facioscapulohumeral dystrophy with cochlear hearing loss and tortuosity of retinal vessels. Am J Med Genet 1985; 22:143–147.
Rogers MT, Zhao F, Harper PS, et al. Absence of hearing impairment in adult onset facioscapulohumeral muscular dystrophy. Neuromuscul Disord 2002; 12:358–365.
Kemp DT. Otoacoustic emissions, their origin in cochlear function, and use. Br Med Bull 2002; 63:223–241.
Pisani V, Tirabasso A, Mazzone S, et al. Early subclinical cochlear dysfunction in myotonic dystrophy type 1. Eur J Neurol 2011; 18:1412–1416.
Balatsouras DG, Korres S, Manta P, et al. Cochlear function in facioscapulohumeral muscular dystrophy. Otol Neurotol 2007; 28:7–10.
Ricci G, Ruggiero L, Vercelli L, et al. A novel clinical tool to classify facioscapulohumeral muscular dystrophy phenotypes. J Neurol 2016; 263:1204–1214.
Lamperti C, Fabbri G, Vercelli L, et al. A standardized clinical evaluation of patients affected by facioscapulohumeral muscular dystrophy: The FSHD clinical score. Muscle Nerve 2010; 42:213–217.
Clark JG. Uses and abuses of hearing loss classification. ASHA 1981; 23:493–500.
American National Standard Specification for Audiometers. ANSI/ASA S3.6-2018 2018 Edition, September 20. American National Standards Institute (ANSI).
Mertes IB, Leek MR. Concurrent measures of contralateral suppression of transient-evoked otoacoustic emissions and of auditory steady-state responses. J Acoust Soc Am 2016; 140:2027–2038.
Trevisan CP, Pastorello E, Ermani M, et al. Facioscapulohumeral muscular dystrophy: A multicenter study on hearing function. Audiol Neurootol 2007; 13:1–6.
Liberman MC, Epstein MJ, Cleveland SS, et al. Toward a differential diagnosis of hidden hearing loss in humans. PLoS One 2016; 11:e0162726.
Barbee CM, James JA, Park JH, et al. Effectiveness of auditory measures for detecting hidden hearing loss and/or cochlear synaptopathy: A systematic review. Semin Hear 2018; 39:172–209.
Ricci G, Cammish P, Siciliano G, et al. Phenotype may predict the clinical course of facioscapolohumeral muscular dystrophy. Muscle Nerve 2019; 59:711–713.
Winokur ST, Barrett K, Martin JH, et al. Facioscapulohumeral muscular dystrophy (FSHD) myoblasts demonstrate increased susceptibility to oxidative stress. Neuromuscul Disord 2003; 13:322–333.
Robin JD, Ludlow AT, Batten K, et al. SORBS2 transcription is activated by telomere position effect-over long distance upon telomere shortening in muscle cells from patients with facioscapulohumeral dystrophy. Genome Res 2015; 25:1781–1790.
Gatica LV, Rosa AL. A complex interplay of genetic and epigenetic events leads to abnormal expression of the DUX4 gene in facioscapulohumeral muscular dystrophy. Neuromuscul Disord 2016; 26:844–852.
Ranum PT, Goodwin AT, Yoshimura H, et al. Insights into the biology of hearing and deafness revealed by single-cell RNA sequencing. Cell Rep 2019; 26: 3160-3171.e3.